Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQFI.L Regulatory News (QFI)

  • There is currently no data for QFI

MOU with Freepoint Commodities LLC

18 Jul 2018 07:00

RNS Number : 9527U
Quadrise Fuels International PLC
18 July 2018
 

18 July 2018

 

Quadrise Fuels International plc

("Quadrise", "QFI" or the "Company")

 

Memorandum of Understanding with Freepoint Commodities LLC

 

The Company is pleased to announce it has signed a Memorandum of Understanding ("MOU") with Freepoint Commodities LLC ("Freepoint").

 

Freepoint, which is based in Stamford, Connecticut, is both an established global merchant of physical commodities and a financer of upper and mid-stream commodity-producing assets. Freepoint also provides physical supply services and related structured solutions for counterparties located throughout the world.

 

Pursuant to the MOU, Quadrise and Freepoint intend to work together to pursue commercial arrangements involving the production and supply of MSAR® fuel to producers and consumers by utilising Quadrise MSAR® technology, additives and services coupled with Freepoint's marketing, trading, logistics and financial services capabilities.

 

Under the MOU, during the next 24 months the parties plan to jointly investigate and pursue selected MSAR® project opportunities in the Americas, with a number of identified counterparties, and in Asia on an exclusive basis with the goal of entering into commercial agreements for MSAR® production and supply arrangements with fuel producers and consumers.

 

Commenting on this development, Mike Kirk, Executive Chairman of QFI, said:

 

"We are delighted to sign this MOU with Freepoint and are confident that with the combination of Quadrise's MSAR® technology and fuel experience, and Freepoint's world-leading oil products trading and financing capabilities, we will be able to progress and accelerate selected MSAR® projects globally."

 

For further information on QFI, please refer to the Company's website at www.quadrisefuels.com, or contact ir@quadrisefuels.com or phone:

 

Quadrise Fuels International Plc

Mike Kirk, Executive Chairman

+44 (0)20 7031 7321

Jason Miles, Chief Operating Officer

Nominated Adviser

Smith & Williamson Corporate Finance Limited

Dr Azhic Basirov

+44 (0)20 7131 4000

Ben Jeynes

Katy Birkin

Broker

Peel Hunt LLP

Richard Crichton

+44 (0)20 7418 8900

Ross Allister 

Public & Investor Relations

FTI Consulting

Ben Brewerton

+44 (0)20 3727 1000

Sara Powell

 

For further information about Freepoint, please refer to Freepoint's website at www.freepoint.com.

 

Notes to Editors

 

QFI is the supplier of MSAR® emulsion technology and fuels, a low-cost alternative to heavy fuel oil (one of the world's largest fuel markets, comprising over 450 million tons per annum) in the global power generation, shipping, steam and refining industries.

 

This announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRLLFITDRIDLIT
Date   Source Headline
10th Dec 20214:41 pmRNSSecond Price Monitoring Extn
10th Dec 20214:36 pmRNSPrice Monitoring Extension
6th Dec 20214:36 pmRNSPrice Monitoring Extension
1st Dec 20218:00 amEQSEdison Investment Research Limited: Quadrise Fuels International (QFI): Cleaner fuel, cleaner planet
26th Nov 20213:30 pmRNSResult of AGM
26th Nov 20217:00 amRNSAGM Statement
1st Nov 20215:00 pmRNSPosting of Annual Report and Notice of AGM
20th Oct 20215:45 pmRNSMorocco Travel Restrictions
5th Oct 20214:41 pmRNSSecond Price Monitoring Extn
5th Oct 20214:35 pmRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSFinal Results, Directorate Change & Notice of AGM
1st Oct 20217:00 amRNSTotal Voting Rights
24th Sep 20217:00 amRNSNotice of Results and Investor Presentation
23rd Sep 20217:00 amRNSUtah Project Update
20th Sep 20214:36 pmRNSPrice Monitoring Extension
3rd Sep 20212:30 pmRNSIssue of Share Options & Director/PDMR Dealing
2nd Sep 20214:40 pmRNSSecond Price Monitoring Extn
2nd Sep 20214:35 pmRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSPublication of bioMSAR Test Results
23rd Aug 20217:00 amRNSGreenfield Commercial Trial Agreement Extension
11th Aug 20217:00 amRNSUpdate on bioMSAR™ Testing
4th Aug 20217:00 amRNSUtah Project Update
30th Jul 20219:30 amRNSBlock Admissions
16th Jul 20214:40 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
16th Jul 20211:15 pmRNSDirectorate Change
28th Jun 20217:00 amRNSUpdate on bioMSAR™ and MSAR® projects
17th May 20214:40 pmRNSSecond Price Monitoring Extn
17th May 20214:35 pmRNSPrice Monitoring Extension
4th May 20219:24 amRNSIssue of Equity
22nd Apr 20214:41 pmRNSSecond Price Monitoring Extn
22nd Apr 20214:36 pmRNSPrice Monitoring Extension
16th Apr 20214:40 pmRNSSecond Price Monitoring Extn
16th Apr 20214:35 pmRNSPrice Monitoring Extension
1st Apr 202112:50 pmRNSUpdate re Greenfield Commercial Trial Agreement
29th Mar 20217:00 amRNSInterim Results
25th Mar 20214:40 pmRNSSecond Price Monitoring Extn
25th Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20217:00 amRNSResults of Open Offer
12th Mar 20217:00 amRNSHolding(s) in Company
10th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSResults of Placing and Open Offer Launch
1st Mar 20214:41 pmRNSProposed Placing and Open Offer
25th Feb 20214:41 pmRNSSecond Price Monitoring Extn
25th Feb 20214:35 pmRNSPrice Monitoring Extension
23rd Feb 20214:36 pmRNSPrice Monitoring Extension
11th Feb 20214:36 pmRNSPrice Monitoring Extension
11th Feb 20217:00 amRNSFinal Issue of Convertible Securities
4th Feb 20214:41 pmRNSSecond Price Monitoring Extn
4th Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.